Page 15 - Sosei Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article TOKYO and CAMBRIDGE, England, May 19, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration between the two companies. Achievement of this milestone triggers a payment of US$5 million to Sosei Heptares. This candidate was nominated for advancement by Pfizer in December 2019 generating a US$3 million milestone payment at that time.   Pfizer nominated three distinct c...

 Global Autism Therapy Market   Global Autism Therapy Market research report has been prepared with a nice combination of industry insight, smart solutions, practical solutions and newest technology to give better user experience. Under market segmentation chapter, research and analysis is done based on several market and industry segments such as application, vertical, deployment model, end user, and geography. To perform this market research study, competent and advanced tools and techniques have been utilized that include SWOT analysis and Porter’s Five Forces Analysis. Businesses can...

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021 News provided by Share this article Share this article TOKYO and CAMBRIDGE, England, May 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2021. The full report can be accessed by clicking here.  Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: "We continue to make good progress expanding our drug discovery business and remain well ...

Share this article Share this article TOKYO and CAMBRIDGE, England, March 11, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has dosed the first patient in a 370-patient randomized Phase 3 clinical trial of APP13007 in the United States (ClinicalTrials.gov Identifier: NCT04739709). APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa. APP13007 was ...

Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020 News provided by Share this article Share this article TOKYO and CAMBRIDGE, England, Feb. 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2020. The full report can be accessed by clicking here.  Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: "Sosei Heptares made a great deal of progress across all areas of its busine...